The document provides definitions of seizures and epilepsy. It then discusses epidemiology, noting incidence and prevalence statistics. Predictors of refractory epilepsy are listed, including early age of onset and structural brain abnormalities. Classification systems for intractable epilepsy are described. Common errors in diagnosis and treatment are reviewed. Mechanisms of drug resistance including multi-drug transporters and drug target alterations are summarized. A therapeutic strategy and treatment algorithm are outlined. Future challenges in management are mentioned.
"..The proposed definition, therefore, is not intended to be prescriptive but represents a working framework. Clinicians and researchers should exercise their judgment in interpreting the principles described in this report when applying the definition to diverse settings.."
-- Kwan P, et al, 2017
Treatment Options for Drug-Resistant Epilepsy
In some people with drug resistant epilepsy, there are effective treatment options, with a high chance of seizure freedom. These include:
Resective Epilepsy Surgery
Resective epilepsy surgery consists of removing the area of the brain that is causing the seizures. However, for a patient to be a good candidate for surgery, the following conditions have to be met:
The area of the brain where seizures originate is clearly identified.
That area of the brain can be safely removed with surgery. In other words if the risk is greater than “minimal risk,” the patient is not a candidate.
The probability to achieve seizure freedom with epilepsy surgery varies depending on the structures of the brain involved. For example, patients whose seizures originate in the temporal lobe have a 50% to 70% chance of achieving seizure-freedom.
Today, newer, less-invasive techniques are being used in the place of resective surgery in appropriate cases. These include the use of laser, in which a laser probe burns the area of the brain causing the seizures. However, these new techniques may not work for all candidates for resective surgery.
Specific Metabolic Treatment
While metabolic causes of epilepsy are uncommon, identifying some of these conditions can lead to specific treatments to allow the body to compensate for the metabolic change.
Examples are treatment with a ketogenic diet for GLUT1 deficiency, treatment with pyridoxine or pyridoxal-5-phosphate for vitamin dependent epilepsies, and creatine supplementation for creatine deficiency syndromes.
Specific Genetic Causes
Identifying a specific genetic cause can help your doctor choose the best treatment for seizures.
For example, with SCN1A pathogenic variants, medications such as Oxcarbazepine (Trileptal), Carbamazepine (Tegretol) or Phenytoin (Dilantin) should be avoided. Whereas with other types of pathogenic variants, such as SCN2A and SCN8A variants, these medications can be very helpful.
Some specific treatments which target the underlying problem caused by the genetic variant are in clinical trials, and may improve learning and development as well as help with seizures.
Immunotherapy
In the last decade, the role of inflammatory processes in certain types of epilepsy has been recognized. In these cases, medications that counteract these processes have been used with success. However, they have to be used with caution as they are associated with a variety of adverse events.
"..The proposed definition, therefore, is not intended to be prescriptive but represents a working framework. Clinicians and researchers should exercise their judgment in interpreting the principles described in this report when applying the definition to diverse settings.."
-- Kwan P, et al, 2017
Treatment Options for Drug-Resistant Epilepsy
In some people with drug resistant epilepsy, there are effective treatment options, with a high chance of seizure freedom. These include:
Resective Epilepsy Surgery
Resective epilepsy surgery consists of removing the area of the brain that is causing the seizures. However, for a patient to be a good candidate for surgery, the following conditions have to be met:
The area of the brain where seizures originate is clearly identified.
That area of the brain can be safely removed with surgery. In other words if the risk is greater than “minimal risk,” the patient is not a candidate.
The probability to achieve seizure freedom with epilepsy surgery varies depending on the structures of the brain involved. For example, patients whose seizures originate in the temporal lobe have a 50% to 70% chance of achieving seizure-freedom.
Today, newer, less-invasive techniques are being used in the place of resective surgery in appropriate cases. These include the use of laser, in which a laser probe burns the area of the brain causing the seizures. However, these new techniques may not work for all candidates for resective surgery.
Specific Metabolic Treatment
While metabolic causes of epilepsy are uncommon, identifying some of these conditions can lead to specific treatments to allow the body to compensate for the metabolic change.
Examples are treatment with a ketogenic diet for GLUT1 deficiency, treatment with pyridoxine or pyridoxal-5-phosphate for vitamin dependent epilepsies, and creatine supplementation for creatine deficiency syndromes.
Specific Genetic Causes
Identifying a specific genetic cause can help your doctor choose the best treatment for seizures.
For example, with SCN1A pathogenic variants, medications such as Oxcarbazepine (Trileptal), Carbamazepine (Tegretol) or Phenytoin (Dilantin) should be avoided. Whereas with other types of pathogenic variants, such as SCN2A and SCN8A variants, these medications can be very helpful.
Some specific treatments which target the underlying problem caused by the genetic variant are in clinical trials, and may improve learning and development as well as help with seizures.
Immunotherapy
In the last decade, the role of inflammatory processes in certain types of epilepsy has been recognized. In these cases, medications that counteract these processes have been used with success. However, they have to be used with caution as they are associated with a variety of adverse events.
Enoxaparin is extensively used in the treatment of venousthrombo-embolic disease (VTED) which inhibits blood clotting inside the blood vessels by the inhibition of factor Xa activity through antithrombin. Local hypersensitivity reactions are one of the rare adverse drug reactions (ADR) of enoxaparin which may lead to hospitalization and excessive burden to the patient. A 72 years male patient was admitted in general medicine department with retrosternal pain even at rest and was diagnosed with unstable angina pectoris. He was administered with anti-coagulantEnoxaparin 0.4ml (40 I.U)subcutaneouslyalong with other supportive medications. Patient have developed severe local hyper sensitivity reactions like erythema,pain,swelling,irritation at the site of injection, and suspected as an ADR of Enoxaparin and immediately drug was withdrawn, then it was confirmed through causality assessment and this ADR have shown +ve for rechallenge;patient was fallowed for improvement and the symptoms especially swelling and irritations were not subsidedeven on 9th day. By this case study we strongly recommend the testingof drug sensitivity before initiating Enoxaparin therapy,and need to collect past history comprehensively for safe and effective outcome of therapy.
Enoxaparin is extensively used in the treatment of venousthrombo-embolic disease (VTED) which inhibits blood clotting inside the blood vessels by the inhibition of factor Xa activity through antithrombin. Local hypersensitivity reactions are one of the rare adverse drug reactions (ADR) of enoxaparin which may lead to hospitalization and excessive burden to the patient. A 72 years male patient was admitted in general medicine department with retrosternal pain even at rest and was diagnosed with unstable angina pectoris. He was administered with anti-coagulantEnoxaparin 0.4ml (40 I.U)subcutaneouslyalong with other supportive medications. Patient have developed severe local hyper sensitivity reactions like erythema,pain,swelling,irritation at the site of injection, and suspected as an ADR of Enoxaparin and immediately drug was withdrawn, then it was confirmed through causality assessment and this ADR have shown +ve for rechallenge;patient was fallowed for improvement and the symptoms especially swelling and irritations were not subsidedeven on 9th day. By this case study we strongly recommend the testingof drug sensitivity before initiating Enoxaparin therapy,and need to collect past history comprehensively for safe and effective outcome of therapy.
Study: The Future of VR, AR and Self-Driving CarsLinkedIn
We asked LinkedIn members worldwide about their levels of interest in the latest wave of technology: whether they’re using wearables, and whether they intend to buy self-driving cars and VR headsets as they become available. We asked them too about their attitudes to technology and to the growing role of Artificial Intelligence (AI) in the devices that they use. The answers were fascinating – and in many cases, surprising.
This SlideShare explores the full results of this study, including detailed market-by-market breakdowns of intention levels for each technology – and how attitudes change with age, location and seniority level. If you’re marketing a tech brand – or planning to use VR and wearables to reach a professional audience – then these are insights you won’t want to miss.
الطّباعة ثلاثيّة الأبعاد هي إحدى تقنيات التصنيع، حيث يتم تصنيع القطع عن طريق تقسيم التصاميم ثلاثية الأبعاد لها إلى طبقات صغيرة جدا باستخدام برامج الحاسوبية ومن ثم يتم تصنيعها باستخدام الطابعات ثلاثية الأبعاد عن طريق طباعة طبقة فوق الأخرى حتى يتكون الشكل النهائي.
تعريف الاقتصاد الرقمي
يعرف الاقتصاد الرقمي بأنه هو النشاط الناتج عن الاتصالات اليومية عبر الإنترنت، كما أن العمود الفقري له هو الارتباط التشعبي، ويعني تزايد الارتباط والترابط بين الأشخاص والمؤسسات والآلات، وتكنولوجيا الهاتف المحمول وإنترنت الأشياء. وهو عموما عبارة عن تصور لقطاع الأنشطة الاقتصادية ذات الصلة بالتقنية الرقمية. وتكون هذه الأنشطة مبنية على النماذج الاقتصادية الكلاسيكية أو الحديثة مثل نماذج الويب
التهديد المستمر المتقدم (Advanced persistent threat): هو مصطلح واسع يستخدم لوصف عملية هجوم يقوم فيها دخيل أو فريق من المتسللين بإنشاء وجود غير قانوني طويل الأمد على الشبكة من أجل استخراج البيانات شديدة الحساسية.
Management of Refractory, Super refractory SE and.pptxsumeetsingh837653
diagnosis and treatment of refractory and super refractory status epilepticus and NORSE
treatment guidelines of status epilepticus
dosages of various antiepileptic used in management of status epilepticus
A review of literature about Stiripentol and Rufinamide and their role in Dravets and Lennox Gastaut Syndrome respectively. It also looks at off label indications of these two orphan drugs.
Abstract: Epilepsy is a serious and common chronic neurological disorder characterized by recurrent seizures, which are caused by abnormal synchronized neuronal disorders. It is a relatively common condition (up to 2% of the population) which can affect anyone at any age. Epilepsy can be controlled in a number of ways. The most common way to treat epilepsy is with anti-epileptic drugs. These AEDs can control but not cure epilepsy. Surgery can also be a possible treatment. Curative epilepsy surgery can only be performed in patients in whom the epileptogenic focus can be localized and does not overlap with eloquent brain areas. In the other patients with bilateral or multiple epileptogenic foci, with epilepsy onset in eloquent areas, or with no identifiable epileptogenic focus, treatments such as ketogenic diet, vagus nerve stimulation can be offered. VNS is an available procedure of which the mechanism of action is not understood, but with established efficacy for refractory epilepsy and low incidence of side-effects. The ketogenic diet is a high-fat, moderate protein, low carbohydrate diet used to treat intractable epilepsy, primary in the pediatric population. Hippocampal Deep Brain Stimulation has been used to treat patients with refractory epilepsy. Complementary and Alternative Medicine for epilepsy such as apuncture, aromatherapy, yoga etc may be used for lessening seizures, for alleviating related symptoms and for reducing side effects. Gene therapy aims to utilize viral and non-viral vectors in the delivery of DNA to target areas for the treatment of patients before their disease progresses. Gene therapy has delivered promising results in animal trials and pre-clinical settings and can be used for neurological disorders such as epilepsy.
Maintenance Electroconvulsive Therapy Augmentation on Clozapine-Resistant Psy...Zahiruddin Othman
Case Report: Maintenance electroconvulsive therapy augmentation on clozapine-resistant psychosis with neurosyphilis is effective and safe but has never been reported in the literature to the authors' knowledge. It is hoped that this case report would contribute to the scarce literature on this augmentation strategy
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
4. Definitions
� Seizure: the clinical manifestation of an
abnormal,
excessive
excitation
and
synchronization of a population of cortical
neurons.
� Epilepsy: recurrent seizures (two or more)
which are not provoked by systemic or acute
neurologic insults.
5. Epidemiology of Seizures and Epilepsy
� Seizures
• Incidence: 80/100,000 per year
• Cumulative lifetime incidence : 9% (1/3
febrile convulsions)
• � Epilepsy
• Incidence: 45/100,000 per year
• Prevalence: 0.5-1%
• Cumulative lifetime incidence: 3%
6.
7.
8. N.B
•At least one of the new AEDs must be used
before considering intractability.
•For the well known epileptic syndromes
with poor prognosis, intractability must be
considered earlier than 2 years.
9. Refractory Status Epilepticus
defined as:
seizures not responding to 1st line (benzodiazapines)
Or / and
2nd line ( phenytoin/ valproates/ phenobarbitone)
agents.
occurs in ~ 20% patients in status epilepticus.
mortality rate > 20%
10. How Serious Is The Problem?
-70% of epileptic pts. have a good prognosis.
-30-40 % may develop refractory epilepsy.
-70% pt retain their intractability versus remission.
-Refractory epileptic pts. are more prone to:
*Neurological and Psychosocial retardation.
*Risk of injury(seizure related).
*High mortality: 1.37 per 100 person-years.
Sudden unexplained death in epilepsy patients (SUDEP) is 40 times
more likely among patients who continue to have seizures than in
those who are seizure free.
11. 2- Predictors For Refractory
Epilepsy
1- Early age of onset.
2- Febrile and neonatal convulsions.
3- History Natal Disorders.
4- Mental subnormality.
5- Organic brain damage.
6- Seizure type, frequency, and number.
7- poor initial response to AED.
12. 8. Status epilepticus
9. Long duration of epilepsy on diagnosis.
10. Abnormal EEG, Abnormal CT.
11. Poor psychological andor socio-economic
background
12. Family history of epilepsy
13. genetic prediction (gene polymorphism )
14. localization of the epileptogenic zone
13. 3- Classification of Intractable
Epilepsy
*Medically intractable epilepsy:
.Pseudo intractable. 1
.True intractable. 2
:Medically and surgically intractable*
.Candidates unfit for surgery. 3
.Candidates with failed surgery. 4
(Aicardi, J.1988)
14. Intractable Epilepsy
Drug resistance may be present→
►
De novo
►
Develop later (MTS):
(Early age of onset, associated Glial proliferation,
dendritic sprouting , synaptic reorginization)
►
Wax-and-wane pattern
17. Diagnostic errors
. Misdiagnosis of non-epileptic seizures.
. Misclassification of epileptic seizures.
. Unrecognized progressive brain disease.
.Failure to uncover precipitating factors.
Misdiagnosis is common; 26 percent of individuals
thought to have DRE were incorrectly diagnosed most
often as a result of incomplete historytaking and/or EEG misinterpretation
18.
19. Treatment errors
. Improper choice of drug.
. Inadequate drug dose.
. Inappropriate combination of drugs.
. Drug interaction.
20.
21. Epilepsy co-morbidities- 5
•
•
•
•
Psychosocial/psychiatric: anxiety,depression
Sleep disorders
Migraine
Cognitive Disorders
NB: Better management of epilepsy comorbidities and QOL improvement → better
seizure control and decrease drug resistance
22. Mechanisms (hypothesis) of- 6
drug resistance in epilepsy
• Two main hypothesis→
IMulti drug-efflux transporters
hypothesis.
II- Drug – target hypothesis.
(Wolfgang L, 2005)
→
23. (I)The multi-drug transporter hypothesis:
•
•
•
•
•
•
•
•
Transporters e.g. P-gp, MRP1,….
Interfere with pharmacological behavior of most drugs.
Mainly P-gp is involved in multi-drug resistance.
Expressed by tissues with excretory function & bloodbrain barrier,blood-testis barrier, placenta.
Over expressed in pts. with refractory epilepsy.
Is this over expression intrinsic or acquired or both ??
Most of the known AED are substrate for these
transporters.
Functional polymorphism of these transporters may
occur and play another role in pharmakoresistance.
24. :II) The Drug-target Hypothesis(
• Target brain molecules include→
► Voltage dependant-ion channels
► Neurotransmitter receptors
► Transporters or metabolic enzymes
involved in release, uptake & metabolism of
neurotransmitters.
• NB.
over
expression
of
multi-drug
transporters, AED-target alterations →
pharmacoresistance
25. Drug Target Alterations
• Decreased efficacy of drugs acting via Na
channels.
• Reduced or lost pharmacosensitivity of Na
channels.
• Down regulation of B1,B2 subunits of Na
channels.
• Decreased efficacy of drugs acting via GABA
mediated inhibition
• Change of GABA receptor subunits (alpha 1,
alpha and delta) expression.
26. 7- Therapeutic strategy for management
of intractable epilepsy
The following measures should be considered in
succession.
1.
Increase the dose of the 1st line antiepileptic drug has
been chosen for the patient, up to the maximum
clinically tolerated dose N.B* we have to treat the
patient not the serum level, On failure→
2.
Change for another drug of the first line drugs, and
also increase its dose gradually up to the maximum
tolerated dose, on failure →
3.
Permanent addition of a second drug, on failure →
27. 4.
At that point we have to do the following:
A. Re-evaluate the patient even with previous normal
investigations.
B. Look for hidden causes and precipitating factors.
C. Psychological assessment
support are needed more here.
and
psychosocial
D. Some questions should be asked now as:
- Can too much of one drug or too many drugs
may not only produce side effects, but also increase
seizures frequency?
- Can certain drug precipitate certain seizure
28. 5. Return to single drug therapy with the best clinically
tolerated of the previously used antiepileptic drugs
(avoid sedative and hypnotic drugs).
6. Addition of one of the new antiepileptic drugs can be
considered
now
as
add
monotherapy, on failure→
on
therapy
or
as
29. 7. We have to consider the following,
7.1-Alternative non antiepileptic drug therapy as add
on therapy under strict clinical selective criteria
such as:
a.Vagal nerve stimulation.
b.ketogenic diet.
c.Hormonal therapy.
d.Calcium antagonists.
e.Intravenous immunoglobulins.
7.2-Epileptic surgery.
30. Treatment Algorithm For Medical Management of Epilepsy
Months of
treatment
Patients with newly diagnosed, previously
untreated epilepsy
0
Monotherapy
(drug 1)
4
Success
Failure
Consider withdrawal after2- 5
years of complete seizure control
Alternative monotherapy
(drug 2)
Success
Failure
Consider withdrawal after 5 years
of complete seizure control
Polytherapy
(drug 1 and 2)
Success
Failure
Consider withdrawal after 5 years
(with patient considerations)
Substitution and transfer to
monotherapy with drug 3
Success
Failure
Consider withdrawal after 5 years
(with patient considerations)
Presurgical evaluation?
Diagnostic re-evaluation
8
12
16
(Gram L & Schmidit D. 2000)
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43. Future challenges- 8
• To develop inhibitors for these transporters
e.g verapamil → inhibitor of P-gp.
• To design effective drugs that are not
substrates for these MDR protein.
• Development of new strategies to by-pass the
effect of these drug transporters.
44.
45.
46. Score for Assessment of Treatment Failure (D Schmidt,1986)
Index of intractability
Seizures persist despite treatment with
0
-A drug other than a 1st line drug regardless of daily
dose.
1
-1st line drug below the recommended daily dose.
2
-1st line drug within the recommended daily dose.
3
-1st line drug with therapeutic range of plasma
concentration.
4
-1st line drug with maximum tolerable dose.
5
-More than one 1st line drug with maximum tolerable
dose.
6
-More than one 1st line drug with maximum tolerable
dose and 2nd line drugs.
Editor's Notes
Sudep 24 t gp
40 seizure free
epilepsy 2-3 t gp
Burns fracture head injury